
|Videos|April 14, 2023
Understanding and Mitigating the Cardiometabolic Risks of ADT
Dr Higano explains how the use of ADT in patients with prostat ecancer may impact metabolic and cardiovascular (CV) risk factors, and shares best practices on optimizing risk assessment, mitigation, and monitoring for these factors.
Advertisement
January 2023 AbbVie Inc. Company Confidential
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Kristen Scarpato, MD, on combination strategies in BCG-naïve NMIBC
2
Trial to compare 225Ac-PSMA-617 vs 177Lu-PSMA-617 for oligorecurrent prostate cancer
3
Farah Rahman, MD, on monitoring resident wellness using biofeedback
4
John Sfakianos, MD, on dual immune checkpoint inhibition in NMIBC
5








